Preclinical approaches in chronic myeloid leukemia: from cells to systems.
Preclinical approaches in chronic myeloid leukemia: from cells to systems.
复制标题
DOI：
10.1016/j.exphem.2016.11.005
复制
发表时间：
2017-03
影响因子：
2.6
通讯作者：
Holyoake TL
中科院分区：
文献类型：
--
作者：
Clarke CJ;Holyoake TL
靶向治疗慢性髓性白血病（CML）的设计进展已经改变了诊断为这种疾病的患者的预后。然而，白血病干细胞的持久性、药物不耐受、耐药性和晚期疾病代表着未满足的临床需求，需要全球CML研究者的关注。适当的临床前模型的可用性对于有效地将研究结果从实验室转化为临床至关重要。在这里，我们回顾了目前在CML领域采取的临床前工作方法，包括常用的体内模型的例子和最近成功的基于系统生物学的方法。CML是一种由染色体易位引起的造血干细胞疾病。tki改变了CML的治疗，但不能根除维持疾病的LSC。综述了目前临床前方法在慢性粒细胞白血病研究中的应用。成功地结合方法交付临床前包进行了讨论。
Advances in the design of targeted therapies for the treatment of chronic myeloid leukemia (CML) have transformed the prognosis for patients diagnosed with this disease. However, leukemic stem cell persistence, drug intolerance, drug resistance, and advanced-phase disease represent unmet clinical needs demanding the attention of CML investigators worldwide. The availability of appropriate preclinical models is essential to efficiently translate findings from the bench to the clinic. Here we review the current approaches taken to preclinical work in the CML field, including examples of commonly used in vivo models and recent successes from systems biology-based methodologies. CML is a hematopoietic stem cell disorder caused by a chromosomal translocation. TKIs have transformed CML treatment but do not eradicate LSC which maintain disease. The current preclinical approaches applied in CML research are reviewed. Successfully combining approaches to deliver preclinical packages is discussed.